General Information of Drug (ID: DMPA5WD)

Drug Name
Harmine Drug Info
Synonyms
Harmine; 442-51-3; 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole; Banisterine; Leucoharmine; Telepathine; Yageine; Yajeine; 7-Methoxy-1-methyl-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 7-methoxy-1-methyl-; Telepathin; Banisterin; Yagein; Harmin; 1-Methyl-7-methoxy-beta-carboline; UNII-4FHH5G48T7; 7-Methoxy-1-methyl-9H-pyrido(3,4-b)indole; Harmin hydrochloride; Harmine, 98%; Banisterine monohydrate; EINECS 207-131-4; 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-; BRN 0178813; 4FHH5G48T7; C13H12N2O; CHEBI:28121; 7-METHOXY-1-METHYL-9H-BETA-CARBOLINE
Cross-matching ID
PubChem CID
5280953
ChEBI ID
CHEMBL269538
CAS Number
CAS 442-51-3
TTD Drug ID
D00OWF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.55 0.00e+0 34/36 (94.44%) MCM4;POLE3;RFC3;...
Cell cycle 2.41 0.00e+0 110/124 (88.71%) CCNH;WEE1;GADD45B;...
Ribosome biogenesis in eukaryotes 2.35 0.00e+0 52/108 (48.15%) GAR1;NXT1;POP7;...
Mismatch repair 2.30 0.00e+0 22/23 (95.65%) MSH6;RFC3;RFC5;...
RNA transport 2.23 0.00e+0 128/186 (68.82%) MAGOH;EIF2S1;EEF1A2;...
Spliceosome 2.14 0.00e+0 101/150 (67.33%) CHERP;MAGOH;PUF60;...
Nucleotide excision repair 2.05 0.00e+0 40/47 (85.11%) CCNH;POLE3;RFC3;...
p53 signaling pathway 1.91 3.84e-3 63/73 (86.3%) GADD45B;CCND3;CDK2;...
Fanconi anemia pathway 1.89 4.10e-3 36/54 (66.67%) USP1;FANCG;FANCA;...
Ribosome 1.86 4.92e-3 113/158 (71.52%) MRPL13;MRPS16;MRPS12;...
Oxidative phosphorylation 1.76 8.94e-3 93/133 (69.92%) NDUFA7;ATP5PF;ATP5MC3;...
Type I diabetes mellitus 1.74 9.73e-3 38/43 (88.37%) CPE;HLA-DOB;GAD1;...
Protein export 1.68 1.99e-2 17/23 (73.91%) SEC62;SEC63;SRP72;...
Basal transcription factors 1.64 2.85e-2 37/45 (82.22%) CCNH;GTF2B;GTF2I;...
Progesterone-mediated oocyte maturation 1.63 3.03e-2 75/100 (75%) CDK2;MAD2L1;IGF1;...
Homologous recombination 1.60 3.80e-2 35/41 (85.37%) RAD54B;SSBP1;RAD51;...
Insulin resistance -1.61 4.83e-2 96/108 (88.89%) CREB5;PIK3CB;PIK3R2;...
IL-17 signaling pathway -1.67 3.96e-2 84/94 (89.36%) MUC5B;TRAF3;TRAF2;...
TNF signaling pathway -1.67 4.05e-2 103/112 (91.96%) JUNB;TRAF3;TRAF2;...
ABC transporters -1.67 4.01e-2 37/45 (82.22%) ABCA7;ABCB6;ABCA2;...
Carbohydrate digestion and absorption -1.68 3.75e-2 37/47 (78.72%) PIK3CA;ATP1B2;PLCB2;...
Natural killer cell mediated cytotoxicity -1.69 3.85e-2 99/131 (75.57%) PIK3CB;PIK3R2;CD247;...
VEGF signaling pathway -1.69 4.01e-2 50/59 (84.75%) MAP2K2;SPHK1;SH2D2A;...
Epithelial cell signaling in Helicobacter pylori infect... -1.70 4.01e-2 62/70 (88.57%) NOD1;ADAM10;CASP3;...
Salmonella infection -1.70 4.13e-2 198/249 (79.52%) TUBB1;RHOG;ACTR2;...
Amino sugar and nucleotide sugar metabolism -1.70 4.32e-2 38/48 (79.17%) HK2;RENBP;GALE;...
Phospholipase D signaling pathway -1.71 4.47e-2 134/148 (90.54%) DGKI;PTK2B;PIK3CG;...
Rheumatoid arthritis -1.72 4.36e-2 78/93 (83.87%) ACP5;HLA-DPB1;ATP6V0E1;...
Neutrophil extracellular trap formation -1.74 3.78e-2 101/189 (53.44%) CASP1;PIK3CB;NCF2;...
Sphingolipid signaling pathway -1.74 3.85e-2 106/119 (89.08%) PPP2R5C;PPP2R5B;RELA;...
Galactose metabolism -1.75 3.67e-2 26/31 (83.87%) HK2;GALE;HK1;...
Lipid and atherosclerosis -1.79 1.78e-2 190/215 (88.37%) PPARG;PPP3CB;NOS3;...
Long-term potentiation -1.79 1.91e-2 61/67 (91.04%) PPP1CA;BRAF;MAP2K2;...
Shigellosis -1.80 1.64e-2 180/246 (73.17%) RRAGD;BECN1;PLCG1;...
GnRH signaling pathway -1.81 1.45e-2 80/93 (86.02%) CAMK2B;ADCY9;EGFR;...
Phosphatidylinositol signaling system -1.85 8.50e-3 82/97 (84.54%) INPPL1;INPP4B;CALML5;...
Legionellosis -1.87 8.01e-3 51/57 (89.47%) CR1;CASP3;RELA;...
Fluid shear stress and atherosclerosis -1.90 4.45e-3 123/139 (88.49%) RAC1;MAP3K5;ITGA2B;...
Mitophagy -1.90 5.01e-3 56/68 (82.35%) USP8;BCL2L13;OPTN;...
Mucin type O-glycan biosynthesis -1.93 5.72e-3 20/36 (55.56%) GCNT3;ST6GALNAC2;GALNT7;...
GnRH secretion -1.95 4.45e-3 60/64 (93.75%) PRKCB;CGA;MAP2K1;...
Ferroptosis -1.99 0.00e+0 36/41 (87.8%) ACSL1;STEAP3;MAP1LC3B;...
Pertussis -1.99 0.00e+0 64/76 (84.21%) C5;CXCL6;IRF1;...
Sphingolipid metabolism -2.05 0.00e+0 32/49 (65.31%) SMPD1;SPHK1;PLPP3;...
Lysosome -2.06 0.00e+0 115/128 (89.84%) ACP5;MAN2B1;MANBA;...
Complement and coagulation cascades -2.18 0.00e+0 76/85 (89.41%) PROC;ITGAX;C5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.37uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 15uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.37uM - 10uM 24H